PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 84 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2013. The put-call ratio across all filers is 4.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $331,000 | -61.9% | 87,041 | -48.9% | 0.00% | 0.0% |
| Q4 2019 | $868,000 | -54.3% | 170,480 | -58.3% | 0.00% | -50.0% |
| Q1 2019 | $1,899,000 | +17.1% | 409,199 | +6.0% | 0.01% | 0.0% |
| Q4 2018 | $1,622,000 | +1128.8% | 386,179 | +2103.6% | 0.01% | +500.0% |
| Q4 2014 | $132,000 | +7.3% | 17,525 | -24.2% | 0.00% | 0.0% |
| Q4 2013 | $123,000 | -15.2% | 23,109 | -29.2% | 0.00% | 0.0% |
| Q2 2013 | $145,000 | – | 32,629 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Phocas Financial Corp. | 1,033,328 | $6,376,000 | 0.68% |
| ARDSLEY ADVISORY PARTNERS LP | 650,000 | $4,011,000 | 0.63% |
| Worth Venture Partners, LLC | 138,357 | $853,000 | 0.47% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,242,503 | $13,836,000 | 0.46% |
| HIGHLAND CAPITAL MANAGEMENT LP | 716,880 | $4,423,000 | 0.26% |
| FARALLON CAPITAL MANAGEMENT LLC | 5,543,386 | $34,203,000 | 0.22% |
| Point72 Asset Management, L.P. | 5,858,749 | $36,148,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,298,723 | $8,013,000 | 0.19% |
| Fosun International Ltd | 472,580 | $2,750,000 | 0.18% |
| J. Goldman & Co LP | 400,000 | $2,468,000 | 0.17% |